Article (Scientific journals)
Focus sur l'empagliflozine. Synthese des analyses post hoc de l'etude cardiovasculaire empa-reg outcome.
Scheen, André
2019In Revue Médicale de Liège, 74 (4), p. 185-191
Peer reviewed
 

Files


Full Text
201904_04.pdf
Publisher postprint (309.38 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Empagliflozin; Heart failure; Mortality; SGLT; Type 2 diabetes; 2 inhibitor; Cardiovascular risk
Abstract :
[en] EMPA-REG OUTCOME trial studied the cardiovascular safety of empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, compared to placebo, in patients with type 2 diabetes and high cardiovascular risk. It showed a significant reduction of major cardiovascular events (-14 %), cardiovascular mortality (-38 %), all-cause death (-32 %), hospitalisations for heart failure (-35 %) and progression of renal disease (-39 %). This article proposes an update, almost 4 years after the original publication, of recent post hoc analyses of this landmark study.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
French
Title :
Focus sur l'empagliflozine. Synthese des analyses post hoc de l'etude cardiovasculaire empa-reg outcome.
Alternative titles :
[en] Focus on empagliflozin : post hoc analyses of the cardiovascular outcome trial EMPA-REG OUTCOME
Publication date :
2019
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
74
Issue :
4
Pages :
185-191
Peer reviewed :
Peer reviewed
Available on ORBi :
since 10 May 2019

Statistics


Number of views
146 (5 by ULiège)
Number of downloads
83 (0 by ULiège)

Scopus citations®
 
2
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi